Gain Therapeutics, Inc. — Form 8-K

Gain Therapeutics, Inc. employed Jeanette Weidner as Vice President, Finance effective October 28, 2026, at an annualized base salary of $275,000 with a 35% target annual bonus. The company granted Weidner an option to purchase 130,000 shares at fair market value, vesting 25% at year one and 75% over 36 months thereafter. Upon termination without cause, death, disability, or good-reason termination, she is entitled to severance equal to base salary during a 6–12 month severance period (12 months if a change of control occurs within 12 months of termination), continuation of health insurance costs via COBRA, and, in a change-of-control termination, acceleration of all unvested equity and a pro-rata bonus.